Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Arginine Vasopressin Deficiency, Oxytocin Deficiency
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Elizabeth Austen Lawson; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sjögren's Syndrome (SS)
Interventions: Dazodalibep, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 41
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Cocaine Use Disorder
Interventions: SXC-2023, SXC-2023 Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Periodontal Diseases, Diabetes, Osteoporosis, Cardiovascular Risk Factor
Interventions: Disease status; Other
Lead sponsor: Tufts University; Other
Eligibility: 45 Years to 100 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: Gout
Interventions: Placebo, Allopurinol, BCX4208; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 18
States / cities: Scottsdale, Arizona • Irvine, California • South Miami, Florida + 15 more

Conditions: Non-small Cell Lung Cancer
Interventions: enzastaurin, placebo, pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Lancaster, California • Los Angeles, California + 7 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interventions: NS-863 Low Dose, NS-863 High Dose, Placebo; Drug · Other
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Bipolar Depression
Interventions: orally-disintegrating olanzapine, regular olanzapine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sciatica
Interventions: Oral Prednisone; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 20 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Schizophrenia
Interventions: NSA-789, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Stroke, Ischemia Stroke, Hemorrhagic Strokes, Mortality, Morbidity, Cerebrovascular Accident (Stroke), Intracerebral Haemorrhage (ICH)
Interventions: Minocycline 200mg; Drug
Lead sponsor: Joyce Chen; Other
Eligibility: 18 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Alzheimer's Disease
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cystic Fibrosis
Interventions: standardized turmeric root extract; Drug
Lead sponsor: Ramsey, Bonnie, MD; Individual
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Bullous Pemphigoid
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Early-stage Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Carcinoma, Renal Cell
Interventions: Recombinant Human Lactoferrin; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Non Alcoholic Steatohepatitis, Fibrosis
Interventions: Idebenone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions: Questionnaires, Tear fluid sampling, Impression Cytology; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

SXC-2023 Cocaine Interaction Study

Genomic Determinants and Shared Genetic Pathways of Periodontal Disease

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Medication, Weight Gain and GI Hormones

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

The Efficacy of Oral Steroids in the Treatment of Acute Sciatica

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

Minocycline in Stroke Study at Maimonides

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye